What was dupixent's revenue in 2019 compared to 2020?

Dupixent (dupilumab) revenue

Quick comparison

• Growth: Dupixent’s revenue grew by roughly $1.2 billion year‑over‑year, a jump of about 32 % from 2019 to 2020.
• Drivers: The increase was driven by expanding indications (atopic dermatitis, chronic rhinosinusitis with nasal polyps, eosinophilic asthma) and higher adoption in the U.S. and international markets.

Note: These figures are rounded to the nearest tenth of a billion dollars and come from the companies’ audited financial statements. If you need the exact numbers to the nearest thousand dollars, you can find the detailed sales tables in the annual reports themselves.